Regorafenib for metastatic colorectal cancer - Authors' reply

Comment

Eric Van Cutsem et al. Lancet. 2013.

. 2013 May 4;381(9877):1538-9.

doi: 10.1016/S0140-6736(13)60978-2.

No abstract available

Comment on

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Grothey A, et al. Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22. Lancet. 2013. PMID: 23177514 Clinical Trial.
Regorafenib for metastatic colorectal cancer.
André T, Raymond E, de Gramont A. André T, et al. Lancet. 2013 May 4;381(9877):1536-7. doi: 10.1016/S0140-6736(13)60975-7. Lancet. 2013. PMID: 23642693 No abstract available.
Regorafenib for metastatic colorectal cancer.
Hyun MH, Shin MR, Kim YH. Hyun MH, et al. Lancet. 2013 May 4;381(9877):1537-8. doi: 10.1016/S0140-6736(13)60977-0. Lancet. 2013. PMID: 23642695 No abstract available.
Regorafenib for metastatic colorectal cancer.
Ricotta R, Sartore-Bianchi A, Verrioli A, Vanzulli A, Siena S. Ricotta R, et al. Lancet. 2013 May 4;381(9877):1537. doi: 10.1016/S0140-6736(13)60976-9. Lancet. 2013. PMID: 23642696 No abstract available.